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FUS metrology. The output of the FUS transducer was calibrated using a piezoelectric 
hydrophone (Onda HGL-0200, Sunnyvale, CA, USA) in a water tank with an ex vivo pig skull. The 
FUS transducer was fixed in the tank and the hydrophone was attached to a motor. A marker was 
used to indicate the approximate tumor location (5 mm posterior from bregma, 5 mm from midline) 
on the top portion of a harvested ex vivo pig skull. The skull was secured in the water tank where 
the marked point was coaxially aligned with the transducer. The axial position of the skull was 
adjusted such that the geometric focus of the transducer would target the tumor implanted depth 
(9 mm from bottom face of skull). Acoustic absorbers were lined in the tank to minimize reflections. 
The focal point of the FUS transducer was identified by raster scanning the hydrophone in the axial 
and lateral plans. The peak negative pressures under different input levels were calculated. The 
axial and lateral full width at half maximums (FWHM) were measured along the axial and lateral 
directions, respectively.   
  
Mouse model of GBM. Immunodeficient mice (strain: NCI Athymic NCr-nu/nu, age: 6-8 
weeks, Charles River Laboratory, Wilmington, MA, USA) were used to generate the xenograft GBM 
model [Ref. 47 in manuscript]. Briefly, mice were anesthetized and the head was fixed on a 
stereotactic device. A sagittal incision was made with a scalpel and a small hole was created using 
a micro-drill at 2.0 mm posterior to bregma and 1.5 mm to the subject’s right from midline. A total 
of 2.0×104 U87-EGFRvIII+ cells in a volume of 5 µL were injected at a depth of 3.5 mm from the 
dura using a sterile Hamilton syringe at a rate of 33 nL/sec. The growth of the tumor was monitored 
using a dedicated 4.7T small animal MRI system (Agilent/Varian DirectDriveTM console, Agilent 
Technologies, Santa Clara, CA, USA). Starting at 7 days and continuing every 3 days thereafter, 
MRI scans were acquired to monitor tumor growth and changes in neuroanatomy. The mice were 
anesthetized under 2% isoflurane and placed in a small animal cradle with an MRI saddle coil 
(Image Guided Therapy, Pessac, France) and stabilized with a bite bar and ear bars. The rectal 
temperature was monitored throughout the experiment and maintained at 37°C. During each 
imaging session, axial T1-weighted gradient echo (repetition time (TR): 108 ms; echo time (TE): 4 
ms; slice thickness: 0.5 mm; in-plane resolution: 0.25×0.25 mm2; matrix size: 128×128; flip angle: 
60°; averages: 16) and axial T2-weighted fast spin echo (TR/TE: 2000/52 ms; slice thickness: 0.5 
mm; in-plane resolution: 0.25´0.25 mm2; matrix size: 128´128; flip angle: 90°; averages: 4) images 
were acquired. 
 
FUS setup for mouse experiment. The annular array design of the FUS transducer allowed 
it to electronically steer the focus in the axial direction. The transducer was connected to an MRI-
compatible piezoelectric motor, allowing the position of the transducer to be mechanically adjusted 
on the horizontal plane. The output of the FUS transducer was calibrated using a hydrophone 
(Onda HGL-0200, Sunnyvale, CA, USA). The axial and lateral FWHM of the FUS transducer were 
5.5 mm and 1.2 mm, respectively. Pressure values were derated to account for the 18% mouse 
skull attenuation [Ref. 101 in manuscript]. Ultrasound gel was carefully placed atop the mouse head 
after the hair was removed with a depilatory cream (Nair, Church & Dwight Co., NJ, USA). 
Deionized and degassed water filled the FUS transducer’s water balloon to ensure sufficient 
acoustic coupling.  
 
MRI analysis. MRI processing and analysis was performed using a custom MATLAB script 
as previously described [Ref. 48 in manuscript]. First, two region-of-interests (ROI) were defined in 
the treated (FUS+) and contralateral (FUS–) hemispheres. In the case of tumor pigs, the FUS– 
area was selected from the parenchyma. Next, a voxel in the FUS+ ROI was considered to contain 
a compromised BBB if the voxel intensity was greater than 3× standard deviations above the mean 
intensity within the FUS– ROI. Then, the volume of contrast enhancement (CE volume) was 
estimated by calculating the sum of FUS+ voxels for each image slice. The analysis was repeated 
pre-FUS and post-FUS. 
 
Sonobiopsy parameter optimization. Enhanced green fluorescence protein (eGFP)-
transfected GL261 murine glioblastoma cells were intracranially implanted to NIH Swiss mice. Mice 





direction, approximately 10 days, as measured by contrast-enhanced T1-weighted scans. First, the 
blood collection time was optimized based on which time point maximized the levels of circulating 
biomarkers. The first three groups had their blood collected either 10 min, 30 min, or 60 min post-
FUS. The optimal time was then used for the rest of the experiment. Second, the optimal FUS 
pressure was evaluated by finding a compromise between increased concentration in biomarkers 
and FUS-induced tissue damage. The three groups for varying FUS pressure were sonicated at 
either 0.5 MPa, 1.0 MPa, or 1.5 MPa. The optimal pressure was selected and used for the 
remainder of the study. Third, the microbubble dose was optimized by comparing biomarkers level 
in the blood with FUS-induced tissue damage. The three groups for optimizing microbubble dose 
were either 8×108 MB/mL (1×), 40×108 MB/mL (5×), or 80×108 MB/mL (10×). The control group 
received no treatment, but the process of MRI acquisition and blood collection remained consistent. 
 
Plasma mRNA analysis. Depending on the treatment group, blood samples were collected 
from the heart 10 min, 30 min, or 60 min post-FUS. The methods of quantitative polymerase chain 
reaction (qPCR) analysis of eGFP mRNA have been described in our previous publication [Ref. 47 
in manuscript]. Briefly, RNA was extracted from the plasma samples using miRNeasy 
serum/plasma kit (Catalog no. 217184, Qiagen, Hilden, Germany) followed by Agencourt 
RNAClean XP beads (Catalog no. A63987, Beckman Coulter Inc., Indianapolis, IN, USA). 
Extracted RNA was then converted to cDNA using the Applied Biosystems high-capacity cDNA 
reverse transcription kit (Catalog no. 4368814, Thermo Fisher Scientific, Waltham, MA, USA). 5.8S 
rRNA was used as the internal control to normalize the PCR data by calculating cycle threshold 
change (DCT) by subtracting CT of the eGFP (CT,eGFP) by the CT of the housekeeping gene, 









Figure S1. Sonobiopsy parameter optimization by qPCR. Quantification of FUS-induced change 
in contrast-enhanced volume (ΔCE volume) volume for different blood collection times post-FUS 
(A), different FUS pressures (B), and different microbubble doses (C). The ΔCE volume was not 
significantly different between each of the treatment groups compared with one another (Kruskal-
Wallis test and post hoc Dunn’s test with Bonferroni correction). FUS-induced biomarker release 
for treatment groups with varying blood collection times (D), FUS pressure (E), and microbubble 
dose (F). There were significant increases in eGFP mRNA levels at 10-min post-FUS blood 
collection (474-fold increase; n = 8, p = 0.0015; **p < 0.01), with FUS pressures of 1.0 MPa (9,694-
fold increase; n = 6, p = 0.03; *p < 0.05) and 1.5 MPa (26,514-fold increase; n = 8, p = 0.0013; **p 
< 0.01) and with microbubble doses of 5× (17,790-fold increase; n = 5, p = 0.0019; **p < 0.01), and 
10× (18,208-fold increase; n = 5, p = 0.0017; **p < 0.01). Statistical analysis was performed with 





LBx. (G) Representative whole-brain horizontal slice shows tumor and hemorrhage. The extent of 
tissue damage, as indicated by hemorrhage density for each treatment group of varying FUS 
pressure (H) and microbubble dose (I). There was no statistical difference between each of the 
treatment groups (n = 3) from one another (Kruskal-Wallis test and post hoc Dunn’s test with 








Figure S2. Fragmentation profile of sonobiopsy-released cfDNA. (A) The average size distribution 
of cfDNA fragment levels were compared in the blood collected after FUS for the sonobiopsy group 
(orange line, n = 8) or without FUS for the blood LBx group (blue line, n = 5). The plasma levels of 
mononucleosomal cfDNA fragments between 140 and 230 bp (gray dashed area) were quantified. 
(B) Sonobiopsy increased the cfDNA levels from 0.030 ± 0.016 pg/µL to 0.056 ± 0.027 pg/µL (mean 









Figure S3. Validation of custom ddPCR primers and probes for detecting EGFRvIII and TERT 
C228T mutations in vitro. (A) Wild type U87 cell line without EGFRvIII expression (U87-EGFRvIII–
) had no detectable copies of EGFRvIII. (B) U87 cell line transfected with EGFRvIII overexpression 
(U87-EGFRvIII+) had positive detection of EGFRvIII. (C) Human embryonic kidney cells (HEK293T) 
had no detectable copies of TERT C228T. (D) ddPCR detected both TERT C228T and TERT wild 








Figure S4. Evaluation of sonobiopsy safety with MRI. (A) T1-weighted MR images confirmed 
consistent BBB disruption at each tumor in the bilateral pig GBM model. (B) Abnormality in T2*-
weighted MR images (blue arrow) indicative of microhemorrhage was observed at the FUS 






Table S1. Sensitivity (±95% confidence intervals) of mutation detection 
 
  Blood LBx Sonobiopsy 
Species Mutation Sensitivity % (95% confidence interval) 
Sensitivity % 
(95% confidence interval) 
Mouse EGFRvIII 7.14 ± 13.49 64.71 ± 22.72 
Mouse TERT C228T 14.91 ± 14.97 45.83 ± 19.93 
Pig EGFRvIII 28.57 ± 33.47 100 ± 0 
Pig TERT C228T 42.86 ± 36.66 71.43 ± 33.47 
 
 
